ASMB — Assembly Biosciences Balance Sheet
0.000.00%
Last trade - 00:00
- $114.66m
- $5.45m
- $7.16m
- 32
- 32
- 85
- 48
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 274 | 216 | 147 | 91.6 | 130 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 3.37 | 1.23 | 0.336 | 0.944 | 0.043 |
Prepaid Expenses | |||||
Total Current Assets | 283 | 224 | 154 | 97 | 134 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 13.8 | 10.7 | 7.18 | 3.94 | 2.72 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 340 | 283 | 191 | 102 | 137 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 24.4 | 24.4 | 16.1 | 16.3 | 39.2 |
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 66.7 | 42.7 | 22.1 | 19.1 | 95.7 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Total Equity | 273 | 241 | 169 | 82.7 | 41.1 |
Total Liabilities & Shareholders' Equity | 340 | 283 | 191 | 102 | 137 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |